Session 10: Drugs. GLP-1 receptor agonists
|
|
- Wendy Ray
- 6 years ago
- Views:
Transcription
1 Session 10: Drugs GLP-1 receptor agonists Dr. Manel Mata La Mina Primary Health Care Centre. Barcelona. Catalonian Institute of Health. Grup DAP_Cat, Barcelona Research Support Unit. IDIAP-Jordi Gol. CIBERDEM. RedGDPS (Spanish Network of Primary Care Groups for the Study of Diabetes)
2 Dr. Manel Mata Session 10: Drugs GLP-1 receptor agonists Conflict of interest disclosure: Honoraria from AstraZeneca, GlaxoSmithKline, Eli Lilly, Novo Nordisk and Sanofi for the participation in advisory boards and lectures about the treatment of diabetes.
3 Session 10: Drugs GLP-1 receptor agonists Agenda - Mechanism of action and benefits - GLP-1ra in the algorithms - GLP-1ra as alternative to basal insulin - GLP-1ra as alternative to prandial insulin added to basal insulin - Adverse Effects. Cardiovascular and pancreatic safety - Key factors when choosing a GLP-1ra - Messages to take home
4 The ideal drug for type 2 diabetes Metformin is the recommended first line agent Safe Efficacious Durable control Well tolerated Low risk of hypoglycaemia Weight neutral or weight loss Reduction of long term complications GLP-1ra are a good option in the second and third steps
5 GLP-1 is released by the small intestine after meal ingestion and enhances glucose-stimulated insulin secretion (incretin action ) Kerr Saraiva F & Sposito AC. Cardiovasc Diabetol. 2014;13(142)
6 Pleiotropic effects of GLP-1 and GLP-1ra Kerr Saraiva F & Sposito AC. Cardiovasc Diabetol. 2014;13(142)
7 GLP-1ra different effects based on the duration of their action in the receptor Exenatide BID Lixisenatide Dulaglutide Exenatide LAR Albiglutide Liraglutide Madsbad S. Diabetes Obes Metab. 2016;18(4):317-32
8 GLP-1 receptor agonists Favorable effects Adverse effects HbA1c Nausea Weight Diarrhea Satiety Vomiting Blood Pressure Heart Rate No Hypoglycaemia Pancreatitis Neutral or CVD Pancreas cancer (?) Brand Name Injection Frequency Usual Dose Clinical Trial Program Exenatide BID Byetta Twice daily 10 μg AMIGO Lixisenatide Lyxumia Once daily 20 mg GetGoal Liraglutide Victoza Once daily mg LEADER Exenatide LAR Bydureon Once weekly 2 mg DURATION Albiglutide Eperzan Once weekly 50 mg HARMONY Dulaglutide Trulicity Once weekly 1.5 mg AWARD
9 GLP-1ra in the algorithm of T2DM treatment
10
11 Need for personalized care: the benefits versus risks of diabetes therapy must be assessed for each patient
12 ADA/EASD Position Statement A patient-centered approach Based on: Preferences, needs and values of the patient Shared decisions Resources and support
13 Patients preferences related to the effects of T2DM treatment Monthly willingess to pay in Denmark N=270 WTP for Beneficial Attributes WTP to avoid detrimental attributes Bøgelund M et al. Curr Med Res Opin 2011;27(11):
14 45-50% of T2DM patients are obese 50-75% of T2DM patients have metabolic syndrome
15 Weight and antidiabetic drugs GLP-1ra SGLT-2i Metformin AGi DPP-4i Glitazones Glinides Sulfonylureas Insulin
16 The consequences of hypoglycaemia Death 2,3 Coma 3 Hospitalisation costs 4 Cardiovascular complications 3 Increased risk of dementia 1 Hypoglycaemia Weight gain due to defensive eating 5 Reduced quality of life 7 Loss of consciousness 3 Increased risk of car accident 6 Increased risk of seizures 3 1 Whitmer RA, et al. JAMA. 2009;301: ; 2 Bonds DE, et al. BMJ. 2010;340:b4909; 3 Barnett AH. Curr Med Res Opin. 2010;26: ; 4 Jönsson L, et al. Value Health. 2006;9: ; 5 Foley JE, Jordan J. Vasc Health Risk Manag. 2010;6: ; 6 Cox DJ. Am J Med Sci. 2013;345:263-5; 7 McEwan P, et al. Diabetes Obes Metab. 2010;12:
17 T2DM treatment choice Risks vs Benefits Benefits HbA1c reduction Reduced complications Safety Hypoglycaemia Weight gain Specific adverse effects Long-term side effects Cost
18 Annual cost of antidiabetic drugs in Spain ArGLP-1 ISGLT-2 IDPP-4 Pioglitazona Inh. α-glucosidases Repaglinida Sulfonilureas Metformina
19 % patients Evolution of new antidiabetic drugs in Catalunya (Spain) from 2007 to ,2 DPP4i 10 6, ,6 5,6 5,8 5,7 4,9 5,2 5,5 3,9 4 3,3 3,7 3,2 2,6 1,5 1,2 0,6 0,1 0,4 0,5 0,7 0,9 Glinides Glitazones GLP1ra
20 2014
21
22
23 GLP-1ra in the 2015 Nice guideline Second Intensification of drug treatment (triple therapy)
24 GLP-1ra in the 2015 Nice guideline Stop if no efficacy (HbA1c+weight loss)
25 GLP1ra vs oral antidiabetic drugs
26 GLP-1ra vs DPP4i in patients treated with Metformin Exenatide LAR vs Sitagliptin 1 Liraglutide vs Sitagliptin 2 Dulaglutide vs Sitagliptin 3 Albiglutide vs Sitagliptin 4 mean HbA1c from baseline (%) Exe 1/w 1.5 Sita 1/d 0.9 Lira 1.8 1/d 1.5 Sita 1/d 0.9 Dula 1.5 1/w Weight 1.6 (kg): Hypos (%) : Sita 1/d 0.4 Albi 1/w 0.6 Sita 1/d Bergenstal et al. Lancet. 2010;376: Pratley et al. Int J Clin Pract. 2011;65: Nauck M et al. Lancet 2014; 384 (9951): Ahrén B, et al. Diabetes Care 2014; 37(8):2141-8
27 GLP1ra vs basal insulin
28 GLP-1ra vs basal insulin in patients treated with Met SU mean HbA1c from baseline (%) Daily Liraglutide 1 LEAD 5 Lira Glargine Weekly Exenatide 2 DURATION 3 Exe Glargine Weekly Albiglutide 3 HARMONY 4 Albi Glargine Weekly Dulaglutide 4 AWARD 2 Dula Glargine Weight 1.6(kg): Hypos (%): Russell-Jones D et al. Diabetologia 2009; 52: Diamant M et a. Diabetes Care. 2012; 35(4): Weissman PN, et al. Diabetologia 2014;57: Georgino F et al. Diabetes Care. 2015;38(12):
29 DURATION-3: 79% of patients treated with Once Weekly Exenatide lost weight and reduced HbA1c vs 31% with Glargine Weight change from baseline (kg) % 63% 0% 5% 12 79% 4% 31% 1% HbA 1c (%) change from baseline Exenatida semanal Insulina glargina Modified ITT population, N=448. Diamant M, et al. Lancet. 2010;375:
30 GLP1ra vs prandial insulin in patients on basal insulin
31 Consider GLP1 ra
32 GLP-1ra vs prandial insulin in patients on basal insulin mean HbA1c from baseline (%) Daily Exenatide vs Lispro 1 EXE 2/d 1.13 Lispro 3/d 1.10 Albiglutide vs Lispro 2 ALBI 1/sem 0.82 Lispro 3/d 0.66 Liraglutide vs Aspart 3 Weight 1.6(kg): Major hypos : LIRA 1/d 0.74 Aspart 1/d 0.39 Lixisenatide vs Glulisine 4 LIXI 1/d 0.6 Glulisine 3/d Diamant M, et al,. Diabetes Care. 2014;37(10): Rosenstock J et al. Diabetes Care 2014; 37(8): Mathieu C et al. Diabetes Obes Metab. 2014;16(7): Rosenstock J et al. Poster ADA 2015; Boston, USA
33 GLP-1ra Gastrointestinal Adverse Effects Pancreatitis and pancreas cancer Cardiovascular Safety
34 GLP1ra Adverse Effects Adverse reactions Albi glutide Place bo Dula glutide 1.5 Place bo Lira glutide 1.8 Place bo Exe natide LAR Place bo Lixi senatide Diarrhea Nausea Vomiting Place bo Injectionsite reactions Heart rate increase (bpm) Ref +2 3 Ref +1 2 Ref 0 Ref 0 Ref No increase in hypoglycaemias Small increase in pancreatitis Risk of pancreas cancer (?)
35 Incretins and Pancreatitis Meta-analysis 55 Randomized trials (N=33,350) 0.11% vs 0.11% (OR 1.11; 0.57 to 2.17) 5 Observational studies (N=320,289) 0.47% vs 0.47% (OR 0.98; 0.69 to 1.38) 1.11 (0.57 to 2.17) Conclusions The available evidence suggests that the incidence of pancreatitis among patients using incretins is low and that the drugs do not increase the risk of pancreatitis. Li L et al. BMJ. BMJ 2014;348:g2366 doi: /bmj.g2366 (Published 14 April 2014)
36 Both agencies agree that assertions concerning a causal association between incretin-based drugs and pancreatitis or pancreatic cancer, as expressed recently in the scientific literature and in the media, are inconsistent with the current data. Although the totality of the data that have been reviewed provides reassurance, pancreatitis will continue to be considered a risk associated with these drugs until more data are available; both agencies continue to investigate this safety signal. Egan AG et al. NEJM 2014; 370(9) Pub Online 27 february 2014
37 ELIXA: Lixisenatide vs placebo in T2DM with a recent coronary event*, mean follow up 2 years. Cumulative incidence (%) Primary endpoint HR (95% CI): (0.886, 1.168) Secondary Variable Heart Failure Hospitalization RR 0,96 Placebo Lixisenatide 0 Number at risk Placebo 3034 Lixisenatide Months * AMI or Unestable Angina in the previous 180 days
38 4/3/16: Novo Nordisk announces that Liraglutide reduces CVD 29/4/16: Novo Nordisk announces that Semaglutide reduces CVD
39 GLP1ra choice based on: Head to Head studies? Efficacy Tolerability Patient convenience? Frequency of injection Device
40 Review of head-to-head comparisons of GLP-1ra Effects on HbA1c HbA1c reduction Liraglutide **** Dulaglutide **** Exenatide OW *** Exenatide BID ** Lixisenatide ** Albiglutide ** Madsbad S. Diabetes Obes Metab. 2016;18(4):317-32
41 Review of head-to-head comparisons of GLP-1ra Effects on Weight Weight reduction Liraglutide **** Dulaglutide *** Exenatide OW *** Exenatide BID *** Lixisenatide *** Albiglutide * Madsbad S. Diabetes Obes Metab. 2016;18(4):317-32
42 GLP1ra Adverse effects in Head to Head studies Gastrointestinal AE Exenatide BID **** Liraglutide **** Dulaglutide **** Exenatide OW *** Lixisenatide ** Albiglutide * Trujillo JM et al. Ther Adv Endocrinol Metab Feb;6(1):19-28
43 Daily GLP 1ra Weekly GLP 1ra Exenatide BID, Byetta Exenatide LAR, Bydureon Liraglutide, Victoza Albiglutide, Eperzan Eperzan TM Lixisenatide, Lyxumia Dulaglutide, Trulicity
44 How to select a GLP-1ra? Use in clinical practice should be customized for individual patients, based on clinical profile and patient preferences HbA1c reduction Weight loss Postprandial effect GI effects Site reactions Frequency injection Device Exenatide BID BID +++ Lixisenatide OD +++ Liraglutide OD +++ Exenatide LAR OW + Albiglutide OW ++ Dulaglutide OW ++++
45 Messages to take home GLP 1ra reduce HbA1c, weight, blood pressure and probably cardiovascular events, but are of limited use in primary care mainly because of its high cost GLP 1ra are preferable in the second and third steps of treatment in obese patients as an alternative to basal or prandial insulin with fewer injections, no need of blood glucose monitoring or dose adjustments Adverse gastrointestinal effects (mainly nausea) are frequent but are usually well tolerated and improve spontaneously after several weeks. Don t use them in patients with history of pancreatitis, gastroparesia or severe renal failure GLP 1ra use in clinical practice should be customized to individual patients, based on their clinical profile and patients preferences
46 Thanks for your attention
47 CV Outcome trials in Type 2 Diabetes ORIGIN Insulin glargine Sanofi (6/ 12) Insulin DPP4 SAVOR TIMI 53 Saxagliptin AZ/BMS (6/ 13) EXAMINE Alogliptin Takeda (12/ 13) TECOS Sitagliptin Merck (12/ 14) LEADER Liraglutide Novo (1/ 16) CAROLINA Linagliptin BI/Lilly (9/ 18) FREEDOM CVO ITCA650 Servier (7/ 17) REWIND Dulaglutide Lilly (4/ 19) MK Omarigliptin MercK (12/ 20) SGLT2 GLP1 SUSTAIN 6 Semaglutide Novo (1/ 16) ELIXA Lixisenatide Sanofi (5/ 14) EXSCEL Exenatide LAR Amylin (3/ 17) CANVAS (interim) Canagliflozin J&J 200 events (subm: 1/ 12) EMPA REG OUTCOME Empagliflozin BI/Lilly (8/ 15) CANVAS (final) Canagliflozin 500 events J&J (/4 17) Ertugliflozin MSD (04/ 20) C SCADE 8 Empagliflozin BI/Lilly (3/ 18) DECLARE Dapagliflozin BMS/AZ (04/ 19)
48 Cardiac effects of GLP-1 and GLP-1ra Ussher JR, Drucker DJ Circ Res. 2014;114(11):
49 GLP1ra vs. DPP4i: HbA1c and weight changes Weight (kg) Bergenstal et al. Lancet. 2010;376: Pratley et al. Int J Clin Pract. 2011;65:
50 Harmony 8: Albiglutide vs Sitagliptin in Renal Impaired Mean (SD) HbA1c (%) Model-Adjusted Albiglutide a Change (N=246) From Sitagliptina Baseline in HbA (N=240) 1c At Week 26 by Severity of Renal Impairment (ITT-LOCF) Mild Moderate Severe 9, , ml/min/1.73 m 2 0,0 8,5 n = n = n = n = n = n = 69 0, Albiglutide 8,0 63 7,5 0,4 0,31 Sitagliptin 57 7,0 0,6 51 6,5 0,8 0,80 0,67 0,61 0, ,0 1, ,2 1,08 Weeks Mean Change From Baseline in HbA 1c, % Number of patients at each a Based point: on analysis of covariance (ANCOVA) Albiglutide Sitagliptin HbA 1c, a % Albiglutide Sitagliptin Model adjusted LS mean change from baseline Treatment difference (albiglutide vs. sitagliptin) (CI 95%) P value for superiority a Efficacy data through week 26 in the safety population using an LOCF analysis Mean (SD) HbA1c mmol/mol 0.32 ( 0.49, 0.15) Leiter LA, et al. Diabetes Care 2014;37: Adapted from Leiter LA, et al. Diabetes Care 2014;37: [Supplement]]
51 Dulaglutide vs sitagliptin vs placebo AWARD-5 trial: 1098 T2DM patients on metformin, 52 weeks HbA1c Weight DU DU Sita Placebo P, 0.001, superiority vs. sitagliptin; P, 0.001, superiority vs. placebo; #, *P, 0.05 vs.sitagliptin and placebo, respectively; ##, **P, vs. sitagliptin and placebo, respectively. Nauck M, et al. Diabetes Care. 2014;37(8):
52 LEAD-5; N=581, 26 weeks HbA1c Triple therapy GLP-1 RA vs Basal insulin Gla -1.1 AE Lira Gla* Lira -1.3 Any hypo 27.4% 28.9% Major hypo 6 0 Diarrhoea 10.0% 1.3% Nausea 13.9% 1.3% *Mean daily dose: 24 UI/day Weight Gla +1.6 Lira -1.8 Russell-Jones D, et al. Diabetologia. 2009;52:
53 HbA1c Triple therapy GLP-1 RA vs Basal insulin DURATION-3; N=415, 84 weeks AE ExeW Gla* Hypos** 12% 40% Hypos*** 36% 56% Diarrhoea 12% 6% Nausea 15% 1% * Mean daily dose: 35 UI/d ** Symptomatic in patients on Met *** Symptomatic in patients on SU+Met Weight Gla -1.0 Exe -1.2 Gla +2.4 Exe -2.1 Diamant M, et al. Diabetes Care. 2012;35(4):683 9.
54 Triple therapy GLP1ra vs Insulin HbA 1c % Glar Albi Hypos 27,4% 17,5% Nausea 3,7% 9,9% Albiglutide (N =496) Glargine* (N =239) Difference: 0.11 (-0.04, 0.27) P no inferiority (margin 0.3)= P superiority = ,67-0, Weight KG ,57-1,06 *Mean daily dose: 30UI Weissman PN, et al. Diabetologia 2014;57:
55 Dulaglutide vs insulin Glargine (AWARD 2) add-on to Metformin ± glimepiride, 78 weeks N=810, 78 weeks Glargine, Dulaglutide 0.75 and 150 mg HbA1c Dula 1.5 Glargina* Hypos 54.4% 69.1% Major Hipos 2 2 Diarrhea 10.6% 5.7% Nausea 15.4% 1.5% * Mean daily dose: 29 UI Weight Georgino F et al. Diabetes Care. 2015;38(12):
56
57 Review of head-to-head comparisons of GLP-1ra Effects on HbA1c Trujillo JM et al. Ther Adv Endocrinol Metab 2015; 6(1):19-28
58 Review of head-to-head comparisons of GLP-1ra Effects on Weight Trujillo JM et al. Ther Adv Endocrinol Metab 2015; 6(1):19-28
Early treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationThe Death of Sulfonylureas? A Review of New Diabetes Medications
The Death of Sulfonylureas? A Review of New Diabetes Medications Kelly Hoenig, Pharm.D., BCPS Cedar Rapids Family Medicine Residency 2/4/17 Objectives Review GLP-1 Agonists, DPP-IV Inhibitors and SGLT-2
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Gretchen Ray, PharmD, PhC, BCACP, CDE Associate Professor, UNM College of Pharmacy January 28, 2018 gray@salud.unm.edu OBJECTIVES Describe the most
More informationrazionale della combinazione insulina/glp-1 RAs
Insulina e GLP-1 RAS: insieme o separati? razionale della combinazione insulina/glp-1 RAs Catania Mercure Catania Excelsior 10 ottobre 2017 Andrea Giaccari andrea.giaccari@unicatt.it Centro per le Malattie
More informationTerapia con agonisti GLP1 e outcome cardiovascolare. Edoardo Mannucci
Terapia con agonisti GLP e outcome cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca,
More informationUpdate on Diabetes Cardiovascular Outcome Trials
Update on Diabetes Cardiovascular Outcome Trials Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research Institute University of Miami Miller School of Medicine
More informationGLP-1 agonists. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
GLP-1 agonists Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What do GLP-1 agonists do? Physiology of postprandial glucose regulation Meal ❶ ❷ Insulin Rising plasma
More informationLa lezione dei trials di safety cardiovascolare. Edoardo Mannucci
La lezione dei trials di safety cardiovascolare Edoardo Mannucci Conflitti di interessi Negli ultimi due anni, E. Mannucci ha ricevuto compensi per relazioni e/o consulenze da: Abbott, AstraZeneca, Boehringer
More informationThe first stop for professional medicines advice
London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1 receptor analogues The first stop for professional medicines advice 1 London Medicines Evaluation Network Overview: Glucagon-Like Peptide-1
More informationCurrent principles of diabetes management
Current principles of diabetes management Prof. Martin Haluzík, MD, DSc. 3 Department of Medicine, General University Hospital and 1st Faculty of Medicine, Charles University in Prague, Czech Republic
More informationCan We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists
Can We Reduce Heart Failure by Treating Diabetes? CVOT Data on SGLT2 Inhibitors and GLP-1Receptor Agonists Robert R. Henry, MD Professor of Medicine University of California, San Diego Relevant Conflict
More informationPreventing Serious Health Consequences of Type 2 Diabetes
Preventing Serious Health Consequences of Type 2 Diabetes The Evidence Hertzel C. Gerstein MD MSc FRCPC Professor and Population Health Institute Chair in Diabetes Research McMaster University and Hamilton
More informationNewer Therapies for Type 2 Diabetes
Newer Therapies for Type 2 Diabetes Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and Metabolism
More informationWhat s New in Type 2 Diabetes? 2018 Diabetes Updates
What s New in Type 2 Diabetes? 2018 Diabetes Updates Jessica Conklin, PharmD, PhC, BCACP, CDE, AAHIP Associate Professor, UNM College of Phar macy jeconklin@salud.unm.edu Luis Gonzales, PharmD, PhC UNM
More informationSelecting GLP-1 RA Treatment
Selecting GLP-1 RA Treatment Dr Felicity Kaplan March 2017 Objectives Review the progressive nature of type 2 diabetes Understand the need for timely treatment intensification Examine the place of GLP-1
More informationDiabetes and Heart Failure: The Role of SGLT2 Inhibitors
22 nd Annual Heart Failure 2018 Symposium Diabetes and Heart Failure: The Role of SGLT2 Inhibitors Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationNavigating the New Options for the Management of Type 2 Diabetes
Navigating the New Options for the Management of Type 2 Diabetes Clinical Associate Professor Mark Kennedy Department of General Practice, University of Melbourne Chair, Primary Care Diabetes Society of
More informationMedical therapy advances London/Manchester RCP February/June 2016
Medical therapy advances London/Manchester RCP February/June 2016 Advances in medical therapies for diabetes mellitus Duality of interest: The speaker or institutions with which he is associated has received
More informationUpdate on Therapies for Type 2 Diabetes: Angela D. Mazza, DO July 31, 2015
Update on Therapies for Type 2 Diabetes: 2015 Angela D. Mazza, DO July 31, 2015 Objectives To present the newer available therapies for the management of T2D To discuss the advantages and disadvantages
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationGLP-1-based therapies in the management of type 2 diabetes
GLP-1-based therapies in the management of type 2 diabetes Makbul Aman Mansyur Division Endocrine & Metabolism Department of Internal Medicine Faculty of Medicine Hasanuddin University/ RSUP Dr. Wahidin
More informationInsulin Initiation and Intensification. Disclosure. Objectives
Insulin Initiation and Intensification Neil Skolnik, M.D. Associate Director Family Medicine Residency Program Abington Memorial Hospital Professor of Family and Community Medicine Temple University School
More informationIncredible Incretins Abby Frye, PharmD, BCACP
Incredible Incretins Abby Frye, PharmD, BCACP Objectives & Disclosures Review the pathophysiology of T2DM and the impact of the incretin system Describe the defining characteristics of the available glucagonlike
More informationOral Agents. Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK
Oral Agents Ian Gallen Consultant Community Diabetologist Royal Berkshire Hospital Reading UK What would your ideal diabetes drug do? Effective in lowering HbA1c No hypoglycaemia No effect on weight/ weight
More informationDM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My!
DM-2 Therapy Update: GLP-1, SGLT-2 Inhibitors, and Inhaled Insulin, Oh My! Kevin M. Pantalone, DO, ECNU, CCD Associate Staff Director of Clinical Research Department of Endocrinology Endocrinology and
More informationLilly Diabetes: Pipeline Update
Lilly Diabetes: Pipeline Update June 16, 2014 Safe Harbor Provision This presentation contains forward-looking statements that are based on management's current expectations, but actual results may differ
More informationOBESITY IN TYPE 2 DIABETES
OBESITY IN TYPE 2 DIABETES Ashley Crowl, PharmD, BCACP Assistant Professor University of Kansas Objectives Review how to manage obesity in patients with type-2 diabetes mellitus Compare antiobesity agents
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationVery Practical Tips for Managing Type 2 Diabetes
Very Practical Tips for Managing Type 2 Diabetes Jean-François Yale, MD, FRCPC McGill University Health Centre, Montreal, Canada Jean-francois.yale@mcgill.ca www.dryale.ca OBJECTIVES DISCLOSURES The participant
More informationAchieving and maintaining good glycemic control is an
Glycemic Efficacy, Weight Effects, and Safety of Once-Weekly Glucagon-Like Peptide-1 Receptor Agonists Yehuda Handelsman, MD, FACP, FNLA, FASPC, MACE; Kathleen Wyne, MD, PhD, FACE, FNLA; Anthony Cannon,
More informationUpdate on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP
Update on Cardiovascular Outcome Trials in Diabetes Jay S. Skyler, MD, MACP Division of Endocrinology, Diabetes, and Metabolism and Diabetes Research InsAtute University of Miami Miller School of Medicine
More informationType 2 diabetes & Cardiovascular disease. update. Barcelona, March 15th 2018
Type 2 diabetes & Cardiovascular disease update Barcelona, March 15th 2018 Francesc Xavier Cos Claramunt Sant Martí de Provençals. Head of Innovation and Health in Barcelona city Assoc.ProfUniversitatAutonomade
More informationDiabete: terapia nei pazienti a rischio cardiovascolare
Diabete: terapia nei pazienti a rischio cardiovascolare Giorgio Sesti Università Magna Graecia di Catanzaro Cardiovascular mortality in relation to diabetes mellitus and a prior MI: A Danish Population
More informationCan Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure?
UCSD Hawaii 2017 Symposium Can Treating Diabetes with SGLT2 inhibitors Prevent Heart Failure? Gregg C. Fonarow, MD, FACC, FAHA Elliot Corday Professor of Cardiovascular Medicine UCLA Division of Cardiology
More informationGLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018
GLP-1 RECEPTOR AGONIST SHOULD I TRY IT? VERONICA BRADY, PHD, BC-ADM, CDE PROJECT ECHO JUNE 21, 2018 SOMETHING TO CONSIDER IF YOU COULD PRESCRIBE A MEDICATION FOR YOUR PATIENT WITH DIABETES THAT: DECREASED
More informationCardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials
Cardiovascular Outcomes With Newer Diabetes Drugs: Results From The EMPA-REG and LEADER Trials Rajiv Roy, MD Endocrinology Sharp Rees-Stealy Medical Group Background Between 1990 and 2010: Incidence of
More informationSTEP THERAPY CRITERIA
CATEGORY DRUG CLASS BRAND NAME (generic) STEP THERAPY CRITERIA AMYLIN ANALOG: SYMLIN/SYMLINPEN (pramlintide acetate) ANTIDIABETIC AGENTS GLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONIST (GLP-1): ADLYXIN (lixisenatide)
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationDR. SUBHASH K. WANGNOO
Photograph DR. SUBHASH K. WANGNOO M.D, D.M, FRCP (London) Senior Consultant, Endocrinologist & Diabetologist Apollo Centre for Obesity, Diabetes and Endocrinology Indraprastha Apollo Hospital, Sarita Vihar,
More informationAlbiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes
St. Onge et al. Medical Research Archives, vol. 5, issue 11, November 2017 issue Page 1 of 10 REVIEW ARTICLE Albiglutide, a Once-Weekly GLP-1RA, for the Treatment of Type 2 Diabetes Erin St. Onge 1*, Shannon
More informationADA Analyst Presentation Saturday 9 th June
ADA Analyst Presentation Saturday 9 th June Carlo Russo Senior Vice-President & Albiglutide Team Leader, GSK Property of GlaxoSmithKline Agenda Welcome & introduction to the Harmony Clinical Programme
More informationType 2 Diabetes Management: Case 1: Reducing Hypoglycemic Risk Case 2: Reducing Cardiovascular Risk
Type 2 Diabetes Management M. Susan Burke, MD, FACP Clinical Associate Professor of Medicine Sidney Kimmel Medical College at Thomas Jefferson University Senior Advisor, Lankenau Medical Associates Lankenau
More informationBeyond A1C. Non-glycemic Effects of GLP-1 Receptor Agonists. Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows
Beyond A1C Non-glycemic Effects of GLP-1 Receptor Agonists Olga Astapova MD, PhD Luis Chavez MD URMC Endocrinology Fellows Disclosures No conflicts of interest. Learning Objectives 1. Understand the physiological
More informationCV outcomes Studies and Implications for diabetes management. Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH
CV outcomes Studies and Implications for diabetes management Seraj Abualnaja, MD, FRCPC Consultant Interventional cardiologist DSFH Case 49 y female with the following medical problems DM typ2 Hypertension
More informationPeter Stein, MD Janssen Research and Development
New Agents and Technologies in the Pipeline for the Treatment of Patients with Diabetes Peter Stein, MD Janssen Research and Development Agents in Phase 3 Development for T2DM Long-acting GLP-1 analogues
More informationINJECTABLE THERAPY FOR THE TREATMENT OF DIABETES
INJECTABLE THERAPY FOR THE TREATMENT OF DIABETES ARSHNA SANGHRAJKA DIABETES SPECIALIST PRESCRIBING PHARMACIST OBJECTIVES EXPLORE THE TYPES OF INSULIN AND INJECTABLE DIABETES TREATMENTS AND DEVICES AVAILABLE
More informationPHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL
Dr Aurora Alcantara Endocrinology PHARMACOLOGIC APPROACH TO ACHIEVE GLYCEMIC GOAL SPED Convention and Diabetes Postgraduate Course May26-29 Wyndham Grand Rio Mar, PR DISCLOSURES Speaker for the following
More informationCOPYRIGHT. Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely?
Treatment of Type 2 Diabetes: What To Do When Treatment with Metformin is Inadequate? Can We Achieve Therapeutic Goals More Safely? Martin J. Abrahamson, MD FACP Associate Professor of Medicine, Harvard
More informationGLP-1RA and insulin: friends or foes?
Tresiba Expert Panel Meeting 28/06/2014 GLP-1RA and insulin: friends or foes? Matteo Monami Careggi Teaching Hospital. Florence. Italy Dr Monami has received consultancy and/or speaking fees from: Merck
More informationGlucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol
Glucagon-like peptide-1 (GLP-1) Agonists Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationMulti-factor approach to reduce cardiovascular risk in diabetes
Multi-factor approach to reduce cardiovascular risk in diabetes Prof. Nicola Napoli, MD PhD Division of Endocrinology and Diabetes Università Campus Bio-Medico di Roma Washington University in St Louis
More informationLet s not sugarcoat it! Update on Pharmacologic Management of Type II DM
Let s not sugarcoat it! Update on Pharmacologic Management of Type II DM Gregory Castelli, PharmD, BCPS, BC-ADM Clinical Pharmacist UPMC St. Margaret Objectives By the end of this presentation, participants
More informationGLUCAGON-LIKE PEPTIDE-1 RECEPTOR AGONISTS FOR TYPE 2 DIABETES: A COMPREHENSIVE
ENDOCRINE PRACTICE Rapid Electronic Article in Press Rapid Electronic Articles in Press are preprinted manuscripts that have been reviewed and accepted for publication, but have yet to be edited, typeset
More informationManagement of Type 2 Diabetes Cardiovascular Outcomes Trials Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas
Management of Type 2 Diabetes Cardiovascular Outcomes Trials 2018 Tom Blevins MD Texas Diabetes and Endocrinology Austin, Texas Speaker Disclosure Dr. Blevins has disclosed that he has received grant support
More informationClinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs
Clinical Relevance of Blood Pressure Lowering Effect of Modern Antidiabetic Drugs Professor Guntram Schernthaner Medical University of Vienna, Austria guntram.schernthaner@meduniwien.ac.at Agenda Glucose
More informationThe Highlights of the AWARD Clinical Program FRANCESCO GIORGINO
The Highlights of the AWARD Clinical Program FRANCESCO GIORGINO DEPARTMENT OF EMERGENCY AND ORGAN TRANSPLANTATION SECTION OF INTERNAL MEDICINE, ENDOCRINOLOGY, ANDROLOGY AND METABOLIC DISEASES Disclaimer
More informationIntensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit?
Intensifying Treatment Beyond Monotherapy in T2DM: Where Do Newer Therapies Fit? Vanita R. Aroda, MD Scientific Director & Physician Investigator MedStar Community Clinical Research Center MedStar Health
More informationTherapeutic strategy to reduce Glucagon secretion
Clinical focus on glucagon: α-cell as a companion of β-cell Therapeutic strategy to reduce Glucagon secretion Sunghwan Suh Dong-A University Conflict of interest disclosure None Committee of Scientific
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More information6/1/2018. Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE
Lou Haenel, IV, DO, FACE, FACOI Endocrinology Roper St Francis Charleston, SC THE OMINOUS OCTET: HOW PATHOPHYSIOLOGY AND THERAPY MERGE 1 2 3 Sulfonylureas Glipizide Glyburide Glimeperide 4 Metformin Gold
More informationPresented By: Creative Educational Concepts, Inc. Lexington, KY
Disclaimer This slide deck in its original and unaltered format is for educational purposes and is current as of April 2015. The content and views presented in this educational activity are those of the
More informationHalting the Rise, Newest Non- Insulin Options for Lowering A1c
Halting the Rise, Newest Non- Insulin Options for Lowering A1c Alecia Rottinghaus, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System January 29 th, 2019 Disclosures Alecia Rottinghaus
More informationHalting the Rise, Newest Non- Insulin Options for Lowering A1c
Halting the Rise, Newest Non- Insulin Options for Lowering A1c Alecia Rottinghaus, PharmD PGY-1 Pharmacy Resident Iowa City Veterans Affairs Health Care System January 29 th, 2019 Disclosures Alecia Rottinghaus
More informationUpdate on Cardiovascular Outcome Trials in Diabetes. Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013
Update on Cardiovascular Outcome Trials in Diabetes Rury R. Holman, FMedSci NIHR Senior Investigator 11 th February 2013 Residual Vascular Risk in People with Diabetes 2 Analyses based on 530,083 participants
More informationWhat s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital
What s New in Type 2? Peter Hammond Consultant Physician Harrogate District Hospital Therapy considerations in T2DM Thiazoledinediones DPP IV inhibitors GLP 1 agonists Insulin Type Delivery Horizon scanning
More informationMANAGING DIABETES IN 2016 WHAT TO ADD, WHEN AND WHY?
MANAGING DIABETES IN 2016 WHAT TO ADD, WHEN AND WHY? Faculty: Maria Wolfs MD, MHSc, FRCPC Assistant Professor, University of Toronto Staff Endocrinologist, St. Michael's Hospital Relationships with commercial
More informationTREATMENTS FOR TYPE 2 DIABETES. Susan Henry Diabetes Specialist Nurse
TREATMENTS FOR TYPE 2 DIABETES Susan Henry Diabetes Specialist Nurse How can we improve outcomes in Type 2 diabetes? Earlier diagnosis Better patient education Stress central role of lifestyle management
More informationUpdate Diabetes Therapie. Marc Y Donath
Update Diabetes Therapie Marc Y Donath Recent CV outcome studies in Diabetes N Engl J Med. 2015 373:2117-28 (Empa-Reg outcome study) N Engl J Med. 2016 June 13 (LEADER trial) N Engl J Med. 2017 June 12
More informationNewer Diabetes Treatments Drug Class Update with New Drug Evaluation: Semaglutide and Ertugliflozin
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationGLP-1 Receptor Agonists and SGLT-2 Inhibitors. Debbie Hicks
GLP-1 Receptor Agonists and SGLT-2 Inhibitors Debbie Hicks Prescribing and Adverse Event reporting information is available at this meeting from the AstraZeneca representative The views expressed by the
More informationSide Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors. Bryce Fukunaga PharmD April 25, 2018
Side Effects of: GLP-1 agonists DPP-4 inhibitors SGLT-2 inhibitors Bryce Fukunaga PharmD April 25, 2018 Objectives For each drug class: Identify the overall place in therapy Explain the mechanism of action
More information9/6/18. Clinical Updates for Nurse Practitioners and Physician Assistants: Faculty. Disclosures
Clinical Updates for Nurse Practitioners and Physician Assistants: 218 Combination Basal Insulin and GLP-1 RA Therapy: A Physiologic Approach to Diabetes Care Faculty Robert S. Busch, MD, FACE Director
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationGLP 1 agonists Winning the Losing Battle. Dr Bernard SAMIA. KCS Congress: Impact through collaboration
GLP 1 agonists Winning the Losing Battle Dr Bernard SAMIA KCS Congress: Impact through collaboration CONTACT: Tel. +254 735 833 803 Email: kcardiacs@gmail.com Web: www.kenyacardiacs.org Disclosures I have
More informationBasal & GLP-1 Fixed Combination Use
Basal & GLP-1 Fixed Combination Use Michelle M. Mangual, MD Diplomate of the American board of Internal Medicine and Endocrinology, Diabetes and Metabolism San Juan City hospital Learning Objectives o
More informationInjectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes
Injectable GLP 1 therapy: weight loss effects seen in obesity with and without diabetes Dr Masud Haq Consultant Lead in Diabetes & Endocrinology Maidstone & Tunbridge Wells NHS Trust & The London Preventative
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationDisclaimers 22/03/2018. Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2
Disclaimers Role of DPP-4 Inhibitors, GLP-1 Agonists, and SGLT-2 Inhibitors in the treatment of Diabetes Mellitus Type 2 I have not received money or gifts from medical device companies or from the pharmaceutical
More informationExploring Non-Insulin Therapies in Type 1 Diabetes
Exploring Non-Insulin Therapies in Type 1 Diabetes Susan Cornell, BS, PharmD, CDE, FAPhA, FAADE Associate Professor Midwestern University - Chicago College of Pharmacy Disclosures Dr. Cornell: Advanced
More informationTYP 2 DIABETES. Marc Donath
TYP 2 DIABETES Marc Donath Treatment of Typ 2 Diabetes GLP-1 Anti-IL-1β Insulin sulfonylureas Metformin UCP-1 IL-1β Sport SGLT2i Bariatric surgery Cardiomyocytes Control Glucose Dyntar et al. Diabetes
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationDept of Diabetes Main Desk
Dept of Diabetes Main Desk 01202 448060 Glucose management in Type 2 Diabetes in Adults The natural history of type 2 diabetes is for HbA1c to deteriorate with time. A stepwise approach to treatment is
More informationMANAGING DIABETES IN 2017 WHAT TO ADD, WHEN AND WHY? December 8, 2017 Maria Wolfs MD MHSc FRCPC
MANAGING DIABETES IN 2017 WHAT TO ADD, WHEN AND WHY? December 8, 2017 Maria Wolfs MD MHSc FRCPC Faculty Disclosure Faculty: Maria Wolfs MD, MHSc, FRCPC Assistant Professor, University of Toronto Endocrinologist,
More informationFrancesca Porcellati
XX Congresso Nazionale AMD Razionali e Benefici dell Aggiunta del GLP-1 RA Short-Acting all Insulina Basale Francesca Porcellati Dipartimento di Medicina Interna, Sezione di Medicina Interna, Endocrinologia
More informationCardiologists and HbA1c: Novel Diabetes Drugs and the Cardiologist as Diabetician
Biomarkers 2019 Cardiologists and HbA1c: Novel Diabetes Drugs and the Cardiologist as Diabetician Gregg C. Fonarow, MD, FACC, FAHA, FHFSA Elliot Corday Professor of Cardiovascular Medicine UCLA Division
More informationOverview T2DM medications. Winnie Ho
Overview T2DM medications Winnie Ho Diabetes in Australia 1.7 million Australians with diabetes, of these 85% have T2DM 2-fold excess risk CV death in patients with diabetes Risk factor for progression
More informationCurrent and future market dynamics overview
OVERVIEW Catalyst Summary EXECUTIVE SUMMARY Strategic scoping and focus Datamonitor key findings Related reports MARKET DEFINITION Published diabetes reports Market definition for antidiabetic drugs Forecast
More informationsitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd
sitagliptin, 25mg, 50mg and 100mg film-coated tablets (Januvia ) SMC No. (1083/15) Merck Sharp and Dohme UK Ltd 07 August 2015 The Scottish Medicines Consortium (SMC) has completed its assessment of the
More informationNovel anti-diabetic therapies
Prof. Manfredi Rizzo, MD, PhD ASSOCIATE PROFESSOR OF INTERNAL MEDICINE School of Medicine University of Palermo, Italy & ASSOCIATE PROFESSOR OF INTERNAL MEDICINE School of Medicine University of South
More informationIl razionale delle associazioni terapeutiche sulla protezione cardiovascolare
Il razionale delle associazioni terapeutiche sulla protezione cardiovascolare Alessandra Dei Cas UOC di Endocrinologia e Malattie del Metabolismo Dipartimento di Medicina e Chirurgia Università di Parma
More informationMaking Sense of New DM Therapies and Technologies
Making Sense of New DM Therapies and Technologies Sandra Indacochea Sobel, MD Clinical Assistant Professor of Medicine Clinical Chief of Endocrinology, UPMC Mercy Division of Endocrinology, Diabetes, and
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationDIABETES DEBATE - IS NEW BETTER?
DIABETES DEBATE - IS NEW BETTER? WHAT MEDICATION CLASS AFTER METFORMIN TO CONTROL BLOOD SUGAR Dr. Lydia Hatcher, MD, CCFP, FCFP, CHE, D-CAPM Associate Clinical Professor of Family Medicine, McMaster Chief
More informationDrug Class Update with New Drug Evaluation: Non-insulin Diabetes Treatments (SGLT-2 Inhibitors and GLP-1 Receptor Agonists)
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationGLP-1 receptor agonists for type 2 diabetes currently available in the U.S.
GLP-1 receptor agonists for type 2 diabetes currently available in the U.S. GLP-1 agonists are a class of antidiabetic agents that mimic the actions of the glucagon-like peptide. GLP-1 is one of several
More informationIn compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants:
In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure to the participants: Entity Activity Financial Consideration Comments Novo Nordisk
More informationCase Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials
Case Studies in Type 2 Diabetes Mellitus: Focus on Cardiovascular Outcomes Trials Louis Kuritzky MD Clinical Assistant Professor Emeritus Department of Community Health and Family Medicine College of Medicine
More informationLATE BREAKING STUDIES IN DM AND CAD. Will this change the guidelines?
LATE BREAKING STUDIES IN DM AND CAD Will this change the guidelines? Objectives 1. Discuss current guidelines for prevention of CHD in diabetes. 2. Discuss the FDA Guidance for Industry regarding evaluating
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More information